Diabetes News You Can Use
Lawmakers voice concern over CMS diabetes device plan
Leaders of the House and Senate Diabetes Caucuses have voiced concerns over a CMS proposal that would include insulin pumps and continuous glucose monitors in a competitive bidding program and change payments to a monthly rental system. The lawmakers said the rule would reduce access to diabetes technology.
Full Story: MedTech Dive (11/4)
Investigative obesity pill shows cardiovascular benefits
Novo Nordisk presented data showing that its experimental weight-loss pill provides cardiovascular benefits and blood sugar control. New analyses of data from the OASIS 4 trial found that a 25-milligram dose of oral semaglutide provided comparable results to injectable semaglutide.
Full Story: Medscape (11/5), Healio (free registration) (11/5)
Fat cell enzyme has gene-regulating role
A study published in the journal Cell Metabolism suggests that the enzyme hormone-sensitive lipase has a previously unknown role in regulating gene activity within the nucleus of fat cells. The findings may lead to new treatments for obesity by focusing on restoring fat cell function.
Full Story: Science (10/23)
Bariatric surgery seen as cost-effective for obesity
Bariatric surgery offers a more cost-effective solution for obesity compared with GLP-1 agonists, experts said at the International Federation for the Surgery of Obesity and Metabolic Disorders World Congress. “If I were the financial adviser of these patients with severe obesity and they asked me which is the appropriate treatment option, I would have a very clear answer,” said Dr. Ildiko Lingvay, an endocrinologist at the University of Texas Southwestern Medical Center.
Full Story: Medscape (10/24)
Automated insulin delivery benefit adults with type 2 diabetes
Automated insulin delivery systems reduced A1C levels for adults with type 2 diabetes regardless of C peptide levels, according to a study in the journal Diabetes Care. The study also found that AID systems increased time in range for both high and low C peptide groups, compared with a control group.
Conclusions: “The benefit of AID is present with high and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted,” the study team wrote.
Full Story: Medscape (10/24)
Fitness apps can be counterproductive
Using fitness apps can cause feelings of shame, frustration and disappointment when goals set by the apps are not achieved, demotivating users, researchers reported in the British Journal of Health Psychology. Researchers analyzed nearly 14,000 social media posts about five popular fitness apps and found evidence of shame, irritation, annoyance and skepticism. The researchers suggested that fitness apps take a more holistic approach and focus on overall well-being.
Full Story: HealthDay News (10/24)
GLP-1s may offer better heart protection for patients with diabetes
Glucagon-like peptide-1 receptor agonists may be the most cardioprotective glucose-lowering agents for patients with type 2 diabetes, particularly those with atherosclerotic cardiovascular disease or heart failure and those 65 and older, according to a study in JAMA Network Open. The study found GLP-1s provided greater protection against major adverse cardiovascular events compared with sulfonylureas, dipeptidyl-peptidase IV inhibitors and SGLT2 inhibitors.
Full Story: Healio (free registration) (10/21)
Costs for ACA health plans to see sharp increase next year
Affordable Care Act health insurance prices are now publicly available for about 12 states, highlighting steep increases unless Congress extends subsidies. In general, plan prices are expected to increase 18% on average in the US next year.
Full Story: The New York Times (10/17)
SGLT2 inhibitors may help older adults with heart disease
A meta-analysis published in the Journal of the American Geriatrics Society found that SGLT2 inhibitors such as empagliflozin and dapagliflozin reduced heart failure hospitalizations and cardiovascular deaths among people ages 65 and older with cardiovascular disease. The analysis of data from 24,889 patients found that the drugs also reduced all-cause mortality, although risk of genital infections increased.
Patients with diabetes: Subgroup analyses, including for patients with type 2 diabetes, also showed significant reductions in risk.
Full Story: Medscape (10/14)
Cardiorenal benefits comparable with 3 GLP-1 drugs
A study in JAMA Network Open found similar cardiorenal outcomes with the GLP-1 receptor agonists semaglutide, liraglutide and dulaglutide among 21,790 military veterans with diabetes. While the risks of kidney failure and major cardiovascular events were comparable, there were differences in all-cause mortality and adverse events.
Full Story: MedPage Today (free registration) (10/13)
Diabetes Research Center
Related News
DRC Affiliate Ian de Boer to Give Garabed Eknoyan Endowed Lectureship
DRC affiliate Ian de Boer, professor (Nephrology) will present the Garabed Eknoyan Endowed Lectureship, “KDIGO Guidelines Decoded: What They Mean for CKD Management in Practice” at the American Society of Nephrology Kidney Week. Named in honor of Garabed Eknoyan, MD, an esteemed researcher, educator, and clinician, the lecture recognizes individuals who have made an impact on or dedicated their lives to the kidney community. More information here.
Congratulations to this year’s funding awardees
Congratulations to this year’s funding awardees: Dr. Nicholas Chavkin and Dr. Stephen McCartney have been awarded Pilot and Feasibility awards and Ms. Jocelyn Cervantes has been awarded the Stroum Graduate Fellowship award.
NIDDK 75th Anniversary
In celebration of the 75th anniversary of NIDDK, Diabetes Care and Diabetes have published a compendium of ten articles that highlight just a few of the major contributions NIIDK has fostered through its support of research. These articles provide a broad, but clearly not complete, view of the results that have been achieved through their fostering of science across the country. Included amongst these is a paper by members of NIDDK about the research centers including the Diabetes Research Centers Program. There is also an editorial that celebrates NIDDK and at the same times raises concerns about the future of research and public health related to diabetes given the current discussion about the funding and restructuring of NIDDK and CDC.
DRC Affiliate Edward Boyko is Co-Chair of New Diabetes Atlas
DRC affiliate, Edward Boyko, professor (General Internal Medicine) is co-chair of the new edition of the International Diabetes Federation (IDF) Diabetes Atlas. As the number of people living with diabetes continues to rise, the latest IDF Diabetes Atlas emphasizes the urgent need for improved prevention, early detection and intervention to tackle the burden diabetes places on individuals, communities, health systems and economies.
Learn more on our news site.
CVTMC Director Karin Bornfeldt Announced as 2025 American Society for Biochemistry and Molecular Biology Fellow
The American Society for Biochemistry and Molecular Biology (ASBMB) announced that CVTMC Director Karin Bornfeldt, professor (Metabolism, Endocrinology and Nutrition), has been named among its 2025 class of fellows. Designation as a fellow recognizes commitment to the ASBMB through a history of exceptional and sustained service to the society as well as impactful accomplishments in research, education, mentorship, and service to the scientific community. Twenty-four fellows were selected this year. Read more here.